Welcome to Pharma Disclosure
This website has been developed as a joint initiative between the European Federation of Pharmaceutical Industries and Associations (EFPIA) and VitalTransformation.com to highlight the industry’s new rules on disclosing financial relationships with doctors and healthcare organisations, follow progress in the implementation and to monitor compliance in the 33 countries involved in the initiative …Read more
In preparation for the implementation of The EFPIA Code outlining the disclosure of transfers of value to healthcare professionals, this webinar is an opportunity to discuss the relationship between practitioners and industry, and how improved transparency will ultimately lead to greater trust and improved patient outcomes.
Breakfast Briefing: Pharmadisclosure.EU – Promoting Greater Collaboration and Trust for Better HealthcareMay 27th 2014 - Silken Berlaymont Hotel, Brussels - 8.30-10.30
A breakfast briefing for stakeholders to showcase and outline the European Federation of Pharmaceutical Industries and Associations (EFPIA) Responsible Transparency initiative for financial and other transfers of value with healthcare professionals and organisations.
by Alastair KentIn a bid to boost drug development, collaboration between the industry and healthcare professionals is intensifying. Financial disclosure will increase transparency, supporting this important shift and speeding patient access to new therapies, says Alastair Kent, Director of Genetic Alliance UK
by Michel BallieuThe move to financial transparency must not be allowed to damage the reputation of healthcare professionals and healthcare organisations. To avoid this, the pharma industry must make the public aware of the pivotal role that its relationship with clinicians has in developing new medicines. The communications campaign should be overseen jointly by the medical profession and the industry, says Michel Ballieu, CEO of the European CanCer Organisation
by Donald SingerThe question of whether there is a need for the pharma industry to consult clinicians and pharmacologists is not at issue. What is critical is that everyone is open about this involvement, says Professor Donald Singer, Secretary of the European Association for Clinical Pharmacology and Therapeutics
by Michel A. DutréeAs EFPIA’s members prepare to make public disclosure of payments to healthcare professionals, Michel Dutrée, Director General of Nefarma describes how the Dutch industry association has taken a lead in establishing a central register, and offers his insights on the process
by Robert SchaeferHealthcare professionals are in favour of transparency, but they have concerns about the practicalities. Not only will the onus to disclose fall to them, there is disquiet about the increasing number and variety of public disclosure platforms, the effect on doctor-patient relationships, and about the lack of public awareness and understanding of what payments are for, says Robert Schaefer